These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 14567522)

  • 1. Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands.
    ten Bokkel Huinink WW; van Groeningen CJ; Voest EE; Peters WG; Keizer HJ; de Witte JH
    Neth J Med; 2003 Jul; 61(7):249-56. PubMed ID: 14567522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
    Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
    Price T; Hill M
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
    Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
    Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.
    Bleiberg H; Cvitkovic E
    Eur J Cancer; 1996; 32A Suppl 3():S18-23. PubMed ID: 8943661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis.
    Sanli UA; Karabulut B; Uslu R; Korkut M; Goker E
    Med Princ Pract; 2006; 15(4):288-92. PubMed ID: 16763396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
    Cunningham D; Pyrhönen S; James RD; Punt CJ; Hickish TF; Heikkila R; Johannesen TB; Starkhammar H; Topham CA; Awad L; Jacques C; Herait P
    Lancet; 1998 Oct; 352(9138):1413-8. PubMed ID: 9807987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
    Berg D
    Oncol Nurs Forum; 1998 Apr; 25(3):535-43. PubMed ID: 9568608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
    Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan in the first-line treatment of colorectal cancer.
    Saltz LB
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):54-8. PubMed ID: 9726092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.
    Nikolic-Tomasevic Z; Jelic S; Popov I; Radosavljevic D
    J Chemother; 2000 Jun; 12(3):244-51. PubMed ID: 10877521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of irinotecan in patients with advanced colorectal cancer in Singapore.
    See HT; Koo WH; Ang P; Au E; Ang PT
    Ann Acad Med Singap; 2002 Sep; 31(5):651-5. PubMed ID: 12395655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
    Kramar A; Gourgou-Bourgade S; Ychou M
    J Clin Oncol; 2005 Jan; 23(3):650; author reply 650-1. PubMed ID: 15659517
    [No Abstract]   [Full Text] [Related]  

  • 15. Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
    Vénat-Bouvet L; Saint-Marcoux F; Lagarde C; Peyronnet P; Lebrun-Ly V; Tubiana-Mathieu N
    Anticancer Drugs; 2007 Sep; 18(8):977-80. PubMed ID: 17667606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
    Desai AA; Kindler HL; Taber D; Agamah E; Mani S; Wade-Oliver K; Ratain MJ; Vokes EE
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):421-6. PubMed ID: 15895230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Mitry E; Ducreux M; Rougier P
    Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E; Blijham GH
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
    Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Van Cutsem E; Peeters M
    Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.